Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03238027
Title A Phase 1, Open-label, Dose Escalation Trial to Investigate SNDX-6352 in Patients With Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Syndax Pharmaceuticals
Indications

Advanced Solid Tumor

Therapies

SNDX-6352

Durvalumab + SNDX-6352

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.